Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: In vitro and in vivo studies

ACS Chemical Neuroscience

Volumn 4, Issue 6, 2013, Pages 973-982

  Abuznait, Alaa H ^a   Qosa, Hisham ^a   Busnena, Belnaser A ^a   El Sayed, Khalid A ^a   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

BBB; LRP1; Oleocanthal; P glycoprotein; amyloid clearance; amyloid degradation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NEUROPROTECTIVE AGENT; OLEOCANTHAL; OLIVE OIL; PHENOL DERIVATIVE; UNCLASSIFIED DRUG; ALDEHYDE; VEGETABLE OIL;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MICROCIRCULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROVASCULATURE;

MUS;

ALDEHYDES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; MALE; MICE; MICE, INBRED C57BL; MICROVESSELS; NEUROPROTECTIVE AGENTS; PHENOLS; PLANT OILS;

EID: 84877120241     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400024q     Document Type: Article

References (47)

1. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., and Evans, D. A. (2004) State-specific projections through 2025 of Alzheimer disease prevalence Neurology 62, 1645
2. Panza, F., Solfrizzi, V., Colacicco, A. M., D'Introno, A., Capurso, C., Torres, F., Del Parigi, A., Capurso, S., and Capurso, A. (2004) Mediterranean diet and cognitive decline Public Health Nutr. 7, 959-963
3. Solfrizzi, V., Panza, F., and Capurso, A. (2003) The role of diet in cognitive decline J. Neural. Transm. 110, 95-110
4. Scarmeas, N., Luchsinger, J. A., Schupf, N., Brickman, A. M., Cosentino, S., Tang, M. X., and Stern, Y. (2009) Physical activity, diet, and risk of Alzheimer disease JAMA, J. Am. Med. Assoc. 302, 627-637
5. Cicerale, S., Lucas, L. J., and Keast, R. S. J. (2012) Oleocanthal: A Naturally Occurring Anti-Inflammatory Agent in Virgin Olive Oil. In Olive Oil-Constituents, Quality, Health Properties and Bioconversions (Dimitrios, B., Ed.), pp 357-374, InTech, Rijeka, Croatia.
6. Corona, G., Spencer, J. P., and Dessi, M. A. (2009) Extra virgin olive oil phenolics: absorption, metabolism, and biological activities in the GI tract Toxicol. Ind. Health 25, 285-293
7. Lopez-Miranda, J., Perez-Jimenez, F., Ros, E., De Caterina, R., Badimon, L., Covas, M. I., Escrich, E., Ordovas, J. M., Soriguer, F., Abia, R., de la Lastra, C. A., Battino, M., Corella, D., Chamorro-Quiros, J., Delgado-Lista, J., Giugliano, D., Esposito, K., Estruch, R., Fernandez-Real, J. M., Gaforio, J. J., La Vecchia, C., Lairon, D., Lopez-Segura, F., Mata, P., Menendez, J. A., Muriana, F. J., Osada, J., Panagiotakos, D. B., Paniagua, J. A., Perez-Martinez, P., Perona, J., Peinado, M. A., Pineda-Priego, M., Poulsen, H. E., Quiles, J. L., Ramirez-Tortosa, M. C., Ruano, J., Serra-Majem, L., Sola, R., Solanas, M., Solfrizzi, V., de la Torre-Fornell, R., Trichopoulou, A., Uceda, M., Villalba-Montoro, J. M., Villar-Ortiz, J. R., Visioli, F., and Yiannakouris, N. (2010) Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaen and Cordoba (Spain) 2008 Nutr., Metab. Cardiovasc. Dis. 20, 284-294
8. Harper, C. R., Edwards, M. C., and Jacobson, T. A. (2006) Flaxseed oil supplementation does not affect plasma lipoprotein concentration or particle size in human subjects J. Nutr. 136, 2844-2848
9. Aguilera, C. M., Mesa, M. D., Ramirez-Tortosa, M. C., Nestares, M. T., Ros, E., and Gil, A. (2004) Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease Clin. Nutr. 23, 673-681
10. Cicerale, S., Lucas, L., and Keast, R. (2010) Biological activities of phenolic compounds present in virgin olive oil Int. J. Mol. Sci. 11, 458-479
11. Beauchamp, G. K., Keast, R. S., Morel, D., Lin, J., Pika, J., Han, Q., Lee, C. H., Smith, A. B., and Breslin, P. A. (2005) Phytochemistry: ibuprofen-like activity in extra-virgin olive oil Nature 437, 45-46
12. Li, W., Sperry, J. B., Crowe, A., Trojanowski, J. Q., Smith, A. B., 3rd, and Lee, V. M. (2009) Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau J. Neurochem. 110, 1339-1351
13. Monti, M. C., Margarucci, L., Tosco, A., Riccio, R., and Casapullo, A. (2011) New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component Food Funct. 2, 423-428
14. Pitt, J., Roth, W., Lacor, P., Smith, A. B., 3rd, Blankenship, M., Velasco, P., De Felice, F., Breslin, P., and Klein, W. L. (2009) Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal Toxicol. Appl. Pharmacol. 240, 189-197
15. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C., and Breteler, M. M. (2002) Dietary intake of antioxidants and risk of Alzheimer disease JAMA, J. Am. Med. Assoc. 287, 3223-3229
16. Solfrizzi, V., Colacicco, A. M., D'Introno, A., Capurso, C., Torres, F., Rizzo, C., Capurso, A., and Panza, F. (2006) Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging Neurobiol. Aging 27, 1694-1704
17. van Assema, D. M., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F., Hoetjes, N. J., Tolboom, N., Langer, O., Muller, M., Scheltens, P., Lammertsma, A. A., and van Berckel, B. N. (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease Brain 135, 181-189
18. Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., and Carare, R. O. (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease Brain Pathol. 18, 253-266
19. Zlokovic, B. V. and Frangione, B. (2003) Transport-clearance hypothesis for Alzheimer's disease and potential therapeutic implications. In Aβ Metabolism in Alzheimer's Disease (Saido, T. C., Ed.), pp 114-122, Landes Bioscience, Georgetown, TX.
20. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., and Zlokovic, B. V. (2000) Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier J. Clin. Invest. 106, 1489-1499
21. Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., and Vogelgesang, S. (2007) MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier Brain Pathol. 17, 347-353
22. Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B., Jiang, H., Prior, J. L., Sagare, A., Bales, K. R., Paul, S. M., Zlokovic, B. V., Piwnica-Worms, D., and Holtzman, D. M. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model J. Clin. Invest. 115, 3285-3290
23. Qosa, H., Abuznait, A. H., Hill, R. A., and Kaddoumi, A. (2012) Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease J. Alzheimer's Dis. 31, 151-165
24. Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., Stopa, E. G., Donahue, J. E., and Johanson, C. E. (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging J. Neuropathol. Exp. Neurol. 69, 1034-1043
25. Vogelgesang, S., Warzok, R. W., Cascorbi, I., Kunert-Keil, C., Schroeder, E., Kroemer, H. K., Siegmund, W., Walker, L. C., and Pahnke, J. (2004) The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease Curr. Alzheimer Res. 1, 121-125
26. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., and Schmidt, A. M. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease Nature 382, 685-691
27. Zlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., McCluskey, R. T., Frangione, B., and Ghiso, J. (1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers Proc. Natl. Acad. Sci. U.S.A. 93, 4229-4234
28. Citron, M. (2010) Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discovery 9, 387-398
29. Abuznait, A. H. and Kaddoumi, A. (2012) Role of ABC Transporters in the Pathogenesis of Alzheimer's Disease ACS Chem. Neurosci. 3, 820-831
30. Lam, F. C., Liu, R., Lu, P., Shapiro, A. B., Renoir, J. M., Sharom, F. J., and Reiner, P. B. (2001) beta-Amyloid efflux mediated by p-glycoprotein J. Neurochem. 76, 1121-1128
31. Abuznait, A. H., Cain, C., Ingram, D., Burk, D., and Kaddoumi, A. (2011) Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease J. Pharm. Pharmacol. 63, 1111-1118
32. Hardy, J. (2006) A hundred years of Alzheimer's disease research Neuron 52, 3-13
33. Zlokovic, B. V., Yamada, S., Holtzman, D., Ghiso, J., and Frangione, B. (2000) Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med. 6, 718
34. Pinto, J., Paiva-Martins, F., Corona, G., Debnam, E. S., Jose Oruna-Concha, M., Vauzour, D., Gordon, M. H., and Spencer, J. P. (2011) Absorption and metabolism of olive oil secoiridoids in the small intestine Br. J. Nutr. 105, 1607-1618
35. Banks, W. A., Robinson, S. M., Verma, S., and Morley, J. E. (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease Neuroscience 121, 487-492
36. Kakee, A., Terasaki, T., and Sugiyama, Y. (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier J. Pharmacol. Exp. Ther. 277, 1550-1559
37. Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., and Holtzman, D. M. (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis Proc. Natl. Acad. Sci. U.S.A. 109, 15502-15507
38. Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G., Stenke, L., Elmhorn-Rosenborg, A., Mollgard, L., Lehman, S., Xu, D., Covelli, A., Gustavsson, B., and Paul, C. (2000) P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia J. Clin. Oncol. 18, 1837-1844
39. El-Amouri, S. S., Zhu, H., Yu, J., Gage, F. H., Verma, I. M., and Kindy, M. S. (2007) Neprilysin protects neurons against Abeta peptide toxicity Brain Res. 1152, 191-200
40. Hemming, M. L., Patterson, M., Reske-Nielsen, C., Lin, L., Isacson, O., and Selkoe, D. J. (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease PLoS Med. 4, e262
41. Poirier, R., Wolfer, D. P., Welzl, H., Tracy, J., Galsworthy, M. J., Nitsch, R. M., and Mohajeri, M. H. (2006) Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit Neurobiol. Dis. 24, 475-483
42. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., and Selkoe, D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death Neuron 40, 1087-1093
43. Elnagar, A. Y., Sylvester, P. W., and El Sayed, K. A. (2011) (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers Planta Med. 77, 1013-1019
44. Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., and Morishita, R. (2010) Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance J. Biol. Chem. 285, 22091-22102
45. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., DeMattos, R. B., and Holtzman, D. M. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life J. Neurosci. 23, 8844-8853
46. Ito, S., Ohtsuki, S., and Terasaki, T. (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier Neurosci. Res. 56, 246-252
47. Twentyman, P. R. and Bleehen, N. M. (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected] Eur. J. Cancer 27, 1639-1642